340P - Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Cancer in Adolescents
Leukaemia
Cancer in Young Adults
Presenter Ranga Raman Ganta
Citation Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586
Authors R.R. Ganta1, S. Nasaka1, V. Linga1, S. Gundeti2, L.S. Maddali2, R. Digumarti3
  • 1Medical Oncology, Nizam's Institute of Medical Sciences, 500082 - Hyderabad/IN
  • 2Dept. Of Medical Oncology, Nizam's Institute of Medical Sciences, 500082 - Hyderabad/IN
  • 3Medical Oncology, Homi Bhabha Cancer Hospital & Research Center, 530053 - Visakhapatnam/IN

Abstract

Background

High body mass index (BMI) has been identified as a poor prognostic factor for several malignancies including chronic myeloid leukemia (CML). To date, studies correlating baseline BMI and response to imatinib in CML are limited. We analyzed our data to study the BMI and its relation with the response rates in adolescent and young adult (AYA) CML CP patients on Imatinib.

Methods

Hospital records of AYA CML CP patients (age 15-29 years) from 2008 to 2012, were analyzed retrospectively for BMI and attainment of cytogenetic and molecular response. They were grouped as low BMI (≤25) and high BMI (>25).

Results

A total of 56 patients were included in this study, with the median age of 21 years and male preponderance (M:F- 1.3:1). Majority (67%) of them had low BMI and rest had high BMI. Complete hematological response rate at 3 months was 100% in both low and high BMI groups. Complete cytogenetic response rate at 12 months was 65% and 89% in low and high BMI groups respectively. Major molecular response rate at 18 months was 78% and 89% in low and high BMI groups respectively. Four year EFS was 100% in both low and high BMI groups.rn

Table: 340P

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn
Low BMI (≤25) n = 38 (67%) High BMI (>25) n = 18 (33%)Fishers test p valve
CHR at 3 month38 (100%)18 (100%)1
CCyR at 12 month25 (65%)16 (89%)0.1
MMR at 18 month30 (78%)16 (89%)0.47
EFS at 4 years38 (100%)18 (100%)1
rn

Conclusions

High BMI CML patients on imatinib showed numerically better response than low BMI patients but statistically not significant. The reasons for these results are not known at present and need to be tested in a prospective study.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.